Buy & Sell National Beverage Corp. (FIZZ) – National Beverage Corp. Price Today
Aura AI Summary
Key Stats
- $3.42BMarket Cap
- Consumer CyclicalSector
- -7.84%3M Drawdown
- $3.17BEnterprise Value
- -Dividend Yield
- 51% Buy | 49% SellTrading Activity
- 28 daysTypical Hold Time
National Beverage Corp. (FIZZ) is currently valued at a market capitalization of $3.42B, with an enterprise value of $3.17B. Over the past 52 weeks, National Beverage Corp. has traded between a low of $31.66 and a high of $47.69, highlighting its annual price range. Over the past three months, National Beverage Corp. has recorded a drawdown of -7.84%, reflecting recent price volatility. On average, investors hold National Beverage Corp. for approximately 28 days, indicating typical investor behavior on the platform.
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Most Recent News
Major mining firms partner with juniors to advance uranium projects through funding and expertise.
Purepoint Uranium CEO Chris Frostad explains that partnerships between major mining companies like Cameco, Orano, and IsoEnergy and junior explorers help advance uranium projects by combining funding, technical expertise, and operational resources. T...
Cullinan Therapeutics shows promising Phase 1 data for CLN-978 in lupus and rheumatoid arthritis patients.
Cullinan Therapeutics presented initial Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, showing clinical benefits including remissions in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The drug demonstra...
Fed cuts rates; dividend stocks like AGNC, Realty Income, and NextEra poised to benefit as yields adjust.
The Federal Reserve has quietly cut interest rates by 75 basis points from 4.5% to 3.75% between late 2025 and early 2026, with expectations of two more cuts in 2026. Despite this, the 10-year Treasury yield remains high at 4.49%, delaying the re-rat...